Benefits of adding glucagon-like peptide 1 receptor agonists to sodium-glucose co-transporter 2 inhibitors in diabetic patients with atherosclerotic disease and heart failure
Lopez PD, Bhatia K, Bohra C, et al.
Am J Cardiol. 2022;S0002-9149(22)00750-0.
Leggi